This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Arno Therapeutics Announces The Appointment Of Mr. Glenn Mattes As President And Chief Executive Officer

Arno Therapeutics, Inc. (ARNI.PK), a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the appointment of Mr. Glenn Mattes as President, Chief Executive Officer and member of the Board of Directors.

“I am very honored and excited to join Arno Therapeutics as President and Chief Executive Officer,” said Mr. Mattes. “Arno currently has three innovative compounds in development that have the potential to be either first or best in class products upon regulatory approval. Arno is well-positioned to execute our comprehensive, global clinical development programs for all three assets as well as additional compounds that Arno may seek to strategically license. I have successfully built market-leading companies throughout my career and believe that my mission is to lead and accelerate the continued growth of Arno. Arno has the potential to become a significant presence in the oncology therapeutic space through the commercialization of novel oncology products that address unmet medical needs.”

"We are delighted to welcome Glenn as President and CEO of Arno. His strategic vision, prior leadership positions, and extensive experience in pharmaceutical development will make him instrumental to the success of Arno as we move our exciting oncology assets through clinical development," said Arie Belldegrun, M.D., Arno’s Chairman of the Board. “In the third quarter of last year, Arno closed on a successful $15 million financing, providing Arno with the funds necessary to continue development of our three product portfolio. I am confident that with Glenn’s leadership, those funds will be put to good use in building value for stockholders and developing much-needed treatments for patients suffering from cancer.”

Mr. Mattes brings over 25 years of commercialization and general management experience that spans a wide range of businesses. During that time, he has established a reputation for leading innovative organizations and developing business in highly specialized and complex therapeutic areas, including oncology. Since 2002, Mr. Mattes served as the President of Tibotec Therapeutics, a Johnson & Johnson operating company focused on oncology and virology therapeutics. At Tibotec, Mr. Mattes led the organization responsible for the development, marketing and sales of novel antiretroviral compounds in North America. Under Mr. Mattes’ leadership, Tibotec successfully launched the first two Johnson & Johnson products in the United States’ HIV/AIDS market. In 2008, Mr. Mattes was appointed to the President’s Advisory Council on HIV/AIDS (PACHA) by the U.S. Secretary of Health and Human Services to counsel White House administrations on both domestic and global health and treatment issues.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,757.91 +138.40 0.79%
S&P 500 2,077.42 +14.31 0.69%
NASDAQ 5,013.1230 +26.2560 0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs